4th Quarter - Report

INFECTIOUS DISEASES SOCIETY OF AMERICA for INFECTIOUS DISEASES SOCIETY OF AMERICA

Firm
Client
Income
—
Expenses
$121,230
Expense method
C: businesses, Internal Revenue Code section 162(e)

What was lobbied

4 issue areas, each in the filer's own words, with who lobbied on it and where.

Medicare/Medicaid MMM

Reimbursement for outpatient infusion therapy; physician payments; Medicaid and Medicare, including Medicare Prescription Drug Coverage; Average Sales Price; Competitive Acquisition Program; infection control; antimicrobial stewardship; and Healthcare Reform.

LobbyistCovered position, as disclosed
ROBERT J GUIDOS V.P. Public Policy & Government Relations
AMANDA JEZEK Government Relations Director
KIMBERLY ANN MILLER HIV Medicine Association Policy Officer

Contacted: Natl Institutes of Health (NIH); Health Resources & Services Administration (HRSA); Health & Human Services, Dept of (HHS); Food & Drug Administration (FDA); Agency for Healthcare Research & Quality (AHRQ); SENATE; Centers For Disease Control & Prevention (CDC); Centers For Medicare and Medicaid Services (CMS); HOUSE OF REPRESENTATIVES

Health Issues HCR

Infectious diseases; drug, diagnostics and vaccine R&D; antimicrobial resistance; antimicrobial stewardship; hospital-acquired infections; immunizations; pandemic influenza, public health security and biodefense; global infectious diseases; biomedical research; reauthorization of PEPFAR; Lyme disease and other infectious diseases issues; Ryan White reauthorization; PAMTA; GAIN Act; STAAR Act; PDUFA

LobbyistCovered position, as disclosed
ROBERT J GUIDOS V.P. Public Policy & Government Relations
AMANDA JEZEK Government Relations Director
KIMBERLY ANN MILLER HIV Medicine Association Policy Officer

Contacted: HOUSE OF REPRESENTATIVES; Centers For Medicare and Medicaid Services (CMS); Health Resources & Services Administration (HRSA); Centers For Disease Control & Prevention (CDC); SENATE; Food & Drug Administration (FDA); Natl Institutes of Health (NIH); Agency for Healthcare Research & Quality (AHRQ); Health & Human Services, Dept of (HHS)

Budget/Appropriations BUD

Funding support for the Department of Health and Human Services, Office of the Biomedical Advanced Research and Development Authority, Centers for Disease Control and Prevention, National Institutes of Health, Health Resources & Services Administration, Food & Drug Administration and global programs for various infectious diseases related issues.

LobbyistCovered position, as disclosed
ROBERT J GUIDOS V.P. Public Policy & Government Relations
AMANDA JEZEK Government Relations Director
KIMBERLY ANN MILLER HIV Medicine Association Policy Officer

Contacted: HOUSE OF REPRESENTATIVES; Health & Human Services, Dept of (HHS); Centers For Disease Control & Prevention (CDC); Centers For Medicare and Medicaid Services (CMS); Agency for Healthcare Research & Quality (AHRQ); Food & Drug Administration (FDA); Health Resources & Services Administration (HRSA); SENATE; Natl Institutes of Health (NIH)

Medical/Disease Research/Clinical Labs MED

Medical liability; antimicrobial resistance research; infectious diseases product research and development; regulatory science; unnecessary regulatory burdens placed on medical research; laboratory developed tests; comparative effectiveness research; support for evidence-based decision making; point-of-care diagnostic tests; and organ transplant policy to allow HIV+ to HIV+ organ transplants.

LobbyistCovered position, as disclosed
ROBERT J GUIDOS V.P. Public Policy & Government Relations
AMANDA JEZEK Government Relations Director
KIMBERLY ANN MILLER HIV Medicine Association Policy Officer

Contacted: Health & Human Services, Dept of (HHS); Food & Drug Administration (FDA); Centers For Disease Control & Prevention (CDC); Health Resources & Services Administration (HRSA); HOUSE OF REPRESENTATIVES; Centers For Medicare and Medicaid Services (CMS); SENATE; Agency for Healthcare Research & Quality (AHRQ); Natl Institutes of Health (NIH)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.